Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.
AR-V7
Castration-resistant prostate cancer
Circulating tumor cells (CTCs)
Predictive biomarkers
Journal
Journal of circulating biomarkers
ISSN: 1849-4544
Titre abrégé: J Circ Biomark
Pays: United States
ID NLM: 101703517
Informations de publication
Date de publication:
Historique:
received:
09
06
2020
accepted:
04
09
2020
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Here we describe the development of a protein immunofluorescent assay for the detection of nuclear-localized androgen receptor variant 7 (AR-V7) protein within circulating tumor cells (CTCs) identified in patient blood samples. Used in the clinic, the test result serves as a validated biomarker of futility for patients with progressing metastatic castration-resistant prostate cancer (mCRPC) who are treated with androgen receptor targeted therapies (AATT) in whom nuclear-localized AR-V7 CTCs are identified and have received level 2A evidence in the 2019 National Cancer Center Network (NCCN) guidelines (v1.0). Assay development was completed on the Epic Sciences rare cell detection platform using control cell lines of known AR-V7 status and clinical testing of mCRPC patient samples obtained at the decision point in management. Using these samples, all assay parameters, scoring criteria, and clinical cutoffs for positivity were prospectively selected and locked. After assay lock, blinded clinical validation testing was initiated on multiple, independent, clinical cohorts as reported by Scher et al (JAMA Oncol. 2016;2:1441-1449; JAMA Oncol. 2018;4:1179-1186) and Armstrong et al (J Clin Oncol. 2019;37:1120-1129).
Identifiants
pubmed: 33717359
doi: 10.33393/jcb.2020.2163
pmc: PMC7951184
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13-19Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020, The Authors.
Déclaration de conflit d'intérêts
Conflict of interest: D. Lu, R. Krupa, M. Harvey, R. Graf, J. Schonhoft, A. Jendrisak, A. Gill, S. Orr are or were employees of Epic Sciences during the writing, data collection, and analysis. H.I. Scher is a consultant/advisory board member for Ambry Genetics Corporation, Amgen, ESSA Pharma, Janssen Biotech, Janssen Research & Development, OncLive Insights, Menarini Silicon Biosystems, Physicians Education Resource, Sanofi Aventis, and WCG Oncology; and he has received institutional research funding from Epic Sciences, Illumina, Janssen Diagnostics, Menarini Silicon Biosystems, and ThermoFisher. No other disclosures are reported.
Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Eur Urol. 2016 Oct;70(4):599-608
pubmed: 27117751
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
J Clin Oncol. 2015 Nov 20;33(33):3968-71
pubmed: 26392104
Eur Urol. 2015 Jan;67(1):53-60
pubmed: 24882673
Clin Genitourin Cancer. 2020 Aug;18(4):284-294
pubmed: 32057714
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
N Engl J Med. 2014 Dec 4;371(23):2234
pubmed: 25470700
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Eur Urol. 2017 Jun;71(6):874-882
pubmed: 27979426
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
Sci Rep. 2015 Jan 07;5:7654
pubmed: 25563505
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
JAMA Oncol. 2018 Sep 1;4(9):1179-1186
pubmed: 29955787
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
J Circ Biomark. 2015 May 5;4:3
pubmed: 28936239